Management of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block
Recruitment status was Not yet recruiting
The primary objective of this study is to propose new treatment algorithm (strategy) for patients with Acute Coronary Syndrome (ACS) and left bundle-branch block (LBBB).
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
- mortality [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Number of participants survived [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
|Study Start Date:||January 2012|
|Estimated Study Completion Date:||November 2013|
|Estimated Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
Current recommendations on the treatment of acute coronary syndrome (ACS) dictate urgent reperfusion therapy in the case of evolving myocardial infarction with ST-segment elevation (STEMI). Optimal use of PCI (preferably) or thrombolysis in this situation requires a rapid and correct diagnosis.
According to the ESC'2008 and ACC/AHA'2009 focused update guidelines patients admitted to the hospital within 12 hours after the onset of chest pain with new (or presumably new) left bundle-branch block (LBBB) should be treated like patients having STEMI (class I, level A). However, it is well-known that in patients with concomitant LBBB, the ECG manifestations of acute myocardial injury may be masked.
ACS may occur in a patient with "true old" LBBB (when doctor has/has not an ability to compare the new ECG with the previous one) or (presumably) new LBBB.
There is a high risk of non receiving appropriate therapy or of receiving inappropriate therapy (thrombolysis instead of LMWH/UFH/fondaparinux).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01494870
|Contact: Dmitry Duplyakov, MD, PhDfirstname.lastname@example.org|
|Contact: Igor Yavelov, MD, PhDemail@example.com|
|Samara Regional Cardiology Dispansery||Not yet recruiting|
|Samara, Russian Federation, 443070|
|Principal Investigator: Dmitry Duplyakov, MD, PhD|